Trial Profile
A Phase 1/2 Multi-center, Randomized, Open-label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of CC-4047 Alone Or in Combination With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Pomalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Celgene Corporation
- 06 Dec 2016 Results of two phase II trials (MM-002 and SIRIUS) and one other trial (MM-003 ) comparing efficacies of pomalidomide plus dexamethasone versus Daratumumab presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 07 Jun 2016 Pooled analysis results from this trial and other two trial (NCT01311687 and NCT01712789) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 05 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov